RT Journal Article
SR Electronic
T1 Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-κB activity via direct interaction with p50
JF Molecular Cancer Therapeutics
JO Mol Cancer Ther
FD American Association for Cancer Research
SP 1613
OP 1624
DO 10.1158/1535-7163.MCT-08-0694
VO 8
IS 6
A1 Ban, Jung Ok
A1 Oh, Ju Hoon
A1 Hwang, Bang Yeon
A1 Moon, Dong Cheul
A1 Jeong, Heon-Sang
A1 Lee, Seram
A1 Kim, Soyoun
A1 Lee, Hyosung
A1 Kim, Kyung-Bo
A1 Han, Sang Bae
A1 Hong, Jin Tae
YR 2009
UL http://mct.aacrjournals.org/content/8/6/1613.abstract
AB Kaurane diterpene compounds have been known to be cytotoxic against several cancer cells through inhibition of nuclear factor-κB (NF-κB) activity. Here, we showed that inflexinol, a novel kaurane diterpene compound, inhibited the activity of NF-κB and its target gene expression as well as cancer cell growth through induction of apoptotic cell death in vitro and in vivo. These inhibitory effects on NF-κB activity and on cancer cell growth were suppressed by the reducing agents DTT and glutathione and were abrogated in the cells transfected with mutant p50 (C62S). Sol-gel biochip and surface plasmon resonance analysis showed that inflexinol binds to the p50 subunit of NF-κB. These results suggest that inflexinol inhibits colon cancer cell growth via induction of apoptotic cell death through inactivation of NF-κB by a direct modification of cysteine residue in the p50 subunit of NF-κB. [Mol Cancer Ther 2009;8(6):1613–24]